Abstract: Several protein kinase inhibitors have been reported to affect cytochrome P450 (CYP) 3A by time-dependent inhibition. Herein, we tested a set of six kinase inhibitors for time-dependent inhibition of CYP2C8 and CYP3A4 in human liver microsomes. Dovitinib, midostaurin and nintedanib exhibited an increased inhibition of CYP3A4 after a 30-min. pre-incubation with NADPH, as compared to no pre-incubation (IC 50 shift >1.5). Masitinib, trametinib and vatalanib did not affect CYP2C8 or CYP3A4 by time-dependent inhibition (IC 50 shift <1.5). The inhibitory mechanism of CYP3A4 by midostaurin and nintedanib, but not by dovitinib, was consistent with irreversible mechanism-based inhibition. The maximal inactivation rate (k inact ) and inhibitor concentration that supports half-maximal rate of inactivation (K I ) values of midostaurin and nintedanib were 0.052 1/min. and 2.72 lM, and 0.025 1/min. and 17.3 lM, respectively. According to static predictions, inactivation of CYP3A4 by nintedanib was unlikely to cause drug-drug interactions with clinically used doses of nintedanib, whereas midostaurin was predicted to increase the plasma exposure to CYP3A4-dependent substrates several fold. Furthermore, based on reversible inhibition, masitinib and vatalanib were predicted to increase the plasma exposure to sensitive CYP2C8 and CYP3A4 substrates by ≥2-fold. In summary, our data identify midostaurin and nintedanib as time-dependent inhibitors of CYP3A4 and detect a risk of drug-drug interactions between vatalanib and CYP2C8 substrates, and between masitinib, midostaurin and vatalanib and CYP3A4 substrates. The liability of kinase inhibitors to affect CYP enzymes by time-dependent inhibition may have long-term consequences, in terms of drug-drug interactions and toxicities.
The introduction of small-molecule protein kinase inhibitors in oncology has markedly improved the treatment of several cancer forms. These compounds target specific mutated or over-expressed protein kinases involved in cancer initiation or progression. In contrast to conventional anticancer therapy, kinase inhibitors are generally taken orally on a daily basis for long periods, because of their favourable pharmacokinetics and low toxicity. However, cancer patients are typically treated with several medications concomitantly, and the frequent long-term administration of kinase inhibitors may lead to a higher risk of drug-drug interactions as compared to conventional anticancer agents [1] .
Most kinase inhibitors undergo extensive metabolism by cytochrome P450 (CYP) enzymes [1] , pre-disposing them to drug-drug interactions caused by CYP inhibitors. In addition, in vitro evidence shows that many kinase inhibitors affect CYP3A4 by time-dependent inhibition [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Although several mechanisms may lead to time-dependent loss of drugmetabolizing enzyme activity, time-dependent inhibition generally refers to enzyme inactivation caused by quasi-irreversible inhibitory metabolite complexes or irreversible covalent adducts, together called mechanism-based inhibitors [17] [18] [19] . Unlike reversible inhibitors, mechanism-based inhibitors permanently disable the affected enzyme. In vitro, the inactivation proceeds in a concentration-, NADPH-and time-dependent manner, because the inhibitor is first metabolized to an intermediate, which then inactivates the metabolizing enzyme. In vivo, mechanism-based inhibition may cause a slow onset but long-lasting inhibition. In addition, besides altering the concentrations of concomitantly administered drugs, mechanism-based inhibitors may affect their own metabolism by time-dependent autoinhibition. Furthermore, sometimes, reactive metabolites formed in these processes may lead to autoimmune reactions and liver toxicities [20] . Of interest, several kinase inhibitors have been reported to induce liver injury [21] , possibly as a consequence of CYP-mediated bioactivation [22] [23] [24] . For these reasons, a careful assessment of the time-dependent inhibitory potential of CYP enzymes by this novel drug class is crucial and of clinical importance.
Because CYP2C8 and CYP3A4 show major overlaps in their substrate specificity [25] , we previously screened a number of kinase inhibitors for their time-dependent inhibitory effects on CYP2C8 and CYP3A4 [2, 3] . We identified bosutinib as a mechanism-based inhibitor of CYP2C8, and imatinib, lestaurtinib and saracatinib as mechanism-based inhibitors of CYP3A4. Of these, at least imatinib can cause clinically relevant interactions via inhibition of CYP3A4; for example, it has increased the plasma concentrations of simvastatin and its active acid form by about threefold to fourfold [26] . For imatinib, mechanism-based inhibition of CYP3A4 also leads to an autoinhibition effect, which reduces the significance of CYP3A4 and makes imatinib metabolism more dependent on CYP2C8 during long-term treatment [27] .
Here, we investigated six novel kinase inhibitors, including dovitinib, masitinib, midostaurin, nintedanib, trametinib and vatalanib, for their potential to affect CYP2C8 and CYP3A4 by time-dependent inhibition. Firstly, we carried out 'inhibitor concentration causing 50% inhibition' (IC 50 ) shift experiments. Thereafter, inhibitors that exhibited an increased inhibition following pre-incubation with NADPH (≥1.5-fold shift in their IC 50 ), as compared to no pre-incubation were further investigated in mechanism-based inhibition experiments. Finally, with use of a mechanistic static model, we carried out predictions to estimate the potential clinical relevance of our in vitro findings.
Materials and Methods
Chemicals. Dovitinib, masitinib, midostaurin, nintedanib (intedanib), trametinib and vatalanib dihydrochloride were purchased from LC Laboratories (Woburn, MA, USA) and saquinavir mesylate from Roche Diagnostics GmbH (Mannheim, Germany). Glutathione, mannitol and superoxide dismutase were obtained from Sigma-Aldrich Inc. (St Louis, MO, USA). Human liver microsomes (HLM) and other chemicals were obtained from the same vendors as in a previous study [3] .
IC 50 -shift experiments. In IC 50 -shift experiments, incubations contained HLM (0.05 mg/ml) in 0.1 M sodium phosphate buffer (pH 7.4). Amodiaquine N-deethylation and midazolam 1 0 -hydroxylation were used as marker reactions for CYP2C8 and CYP3A4 activity, respectively. The concentrations of amodiaquine and midazolam used in the incubations (2 lM) corresponded to their Michaelis-Menten constant (K m ) for CYP2C8 and CYP3A4 [28] . Inhibitor concentrations ranged from 0.005 to 500 lM, depending on the inhibitor tested. In direct (reversible) inhibition incubations, inhibitor or solvent control and substrate were pre-mixed with HLM and buffer for 3 min. before addition of 1.0 mM NADPH, which initiated the reactions. In timedependent inhibition incubations, the inhibitor or solvent control was pre-incubated with HLM and NADPH for 30 min., before addition of substrate. The final incubations were performed in a shaking water bath (37°C) for 2 min.
Kinetic assessment and follow-up experiments. Dovitinib, midostaurin and nintedanib caused a >1.5-fold reduction in their IC 50 for CYP3A4 following a 30-min. pre-incubation with NADPH, as compared to no pre-incubation [29] , and were therefore selected for kinetic assessment. Briefly, various inhibitor concentrations were preincubated with 0.5 mg/ml HLM and 1.0 mM NADPH for up to 30 min. At determined time-points, an aliquot of 15 ll pre-incubation mixture was moved to another tube and further incubated for 2 min. This tube contained 1.0 mM NADPH and 10 lM midazolam with buffer, to give a final incubation volume of 300 ll. Accordingly, the protein and inhibitor concentrations had been diluted 20-fold, and a substrate concentration five times higher than its K m was used to minimize direct inhibition by the inhibitors.
Dovitinib did not cause inactivation in the kinetic assessment including 20-fold dilution and was not investigated further. However, to determine the effect of a competitive inhibitor on the timedependent inactivation of CYP3A4 by midostaurin and nintedanib, pre-incubation mixtures were prepared as above. Pre-incubations were carried out with or without ketoconazole (0.01-1 lM) as a competitive CYP3A4 inhibitor, both in the absence (control) and presence of midostaurin (30 lM) or nintedanib (34 lM). Mixtures were then preincubated for 30 min.; aliquots were transferred to incubation tubes (20-fold dilution), and the residual midazolam 1 0 -hydroxylation activity was measured. Moreover, because ketoconazole did not affect the inactivation of CYP3A4 by midostaurin, further experiments with midostaurin were carried out. In the experiments, midostaurin was incubated with another CYP3A4 inhibitor, saquinavir (0.1-3 lM) and trapping agents, including glutathione (2 mM), mannitol (1 mM) and superoxide dismutase (1000 U/ml), using the same experimental conditions as in the ketoconazole assay.
To evaluate the effect of dialysis on the inhibitory effects of midostaurin and nintedanib, HLM (0.5 mg/ml) were pre-incubated with or without inhibitor (30 lM midostaurin or 34 lM nintedanib) and NADPH for 30 min. The pre-incubation mixtures were then immediately dialysed against 0.1 M sodium phosphate buffer (pH 7.4) three times for 2 hr in a volume of 2 l at 4°C, followed by a 20-fold dilution and measurement of CYP3A4 activity.
Measurement of drug concentrations. Reactions were stopped by moving 100 ll of sample to 300 ll of 0.3% formic acid in 90/5/5 acetonitrile/methanol/water containing N-desethylamodiaquine-d5 and triazolam as internal standards. Samples were thereafter handled as previously described [2] . Amodiaquine, ketoconazole, midazolam, midostaurin and saquinavir were dissolved in methanol; nintedanib and vatalanib in ethanol; and dovitinib, masitinib and trametinib in DMSO. In IC 50 experiments, the final solvent concentration in all incubations (including controls) with inhibitors dissolved in methanol and ethanol was 1%, whereas in all incubations (including controls) for the other inhibitors it was 0.2%. In mechanism-based experiments with midostaurin and nintedanib, the solvent concentration was ≤1%. Incubations were performed in duplicates (controls in triplicates), and the incubation time was within the linear range for the rates of metabolite formation.
Sample handling and determination of N-desethylamodiaquine and 1 0 -hydroxymidazolam concentrations using an Agilent 1100 series high-performance liquid chromatography system (Agilent Technologies, Waldbronn, Germany) coupled to a SCIEX API 2000 tandem mass spectrometer (MDS Sciex, Concord, ON, Canada) were conducted as previously described [2] . The lower limit of quantification was 0.001 lM for N-desethylamodiaquine and 0.002 lM for 1 0 -hydroxymidazolam. The interday coefficient of variation for N-desethylamodiaquine was 14% at 0.001 lM, 13% at 0.01 lM, and 8% at 0.1 lM, and for 1 0 -hydroxymidazolam it was 15% at 0.002 lM, 14% at 0.02 lM and 7% at 0.2 lM.
Data analysis. IC 50 values were determined by nonlinear regression analysis using GraphPad Prism (version 7.00; GraphPad Software, Inc, La Jolla, CA, USA). For estimation of mechanism-based inhibition constants, pre-incubation time-dependent loss of CYP3A4 activity in the absence of the inhibitor was accounted for by adjusting the observed metabolism rate with reference to the respective control (vehicle) incubation at each pre-incubation time. The initial rate constant of CYP enzyme inactivation (K obs ) by each inhibitor concentration [I] was determined by linear regression analysis of the natural logarithm of the initial linear portion of the plotted percentage of activity remaining versus pre-incubation time [30] . Thereafter, the K obs values were used to determine the maximum inactivation rate (k inact ) and the inhibitor concentration needed to cause half of k inact (K I ). These values were estimated by nonlinear regression using the equation: [30, 31] .
Drug-drug interaction predictions. Reversible IC 50 and timedependent K I and k inact values were used for predictions of the potential clinical impact of the inhibition of CYP2C8 or CYP3A4. For substrates that are metabolized in both intestine and liver, a mechanistic static model has been developed to simultaneously evaluate the clinical impact of reversible inhibition, time-dependent inhibition and induction [32, 33] . Herein, we used the model, but excluded the induction term as follows:
where AUC R denotes the change in the area under the concentration-time curve of the substrate in the presence of an inhibitor as compared to its absence, f m expresses the fraction of substrate metabolized by the CYP enzyme that is subject to the inhibition, and F G describes the fraction of substrate available after intestinal extraction. A and C describe timedependent inhibition and reversible inhibition, respectively:
where q denotes either liver (H) or intestine (G), and k deg is the rate constant of hepatic or intestinal CYP degradation in the absence of the inhibitor. The inhibition of CYP3A observed in our incubations was assumed to be completely due to inhibition of CYP3A4; thus, 36 and 23 hr were used as the CYP3A4 half-life in the liver and intestine, respectively (corresponding to k deg values of 0.00032 and 0.00050 1/min.) [34] [35] [36] . Furthermore, we assumed that reversible inhibition of CYP2C8 and CYP3A4 was competitive. Reversible inhibition constant (K i ) values were thus calculated according to the equation
, where [S] denotes substrate concentration. Predictions based on inhibition of hepatic CYP2C8 and CYP3A4 were conducted using unbound hepatic inlet peak concentrations, [I] u,inlet,max , for reversible inhibition and unbound steady-state concentrations, [I] max,u , for mechanism-based inhibition [38] .
[I] u,inlet,max values were calculated according to the following equation [39] :
where f u,b is the unbound fraction in blood (calculated based on f u in plasma divided by the blood-to-plasma ratio (B/P); table 1), [I] max,b is the total peak concentration in the blood, Q h represents the sum of blood flow in the hepatic artery and portal vein (20.7 ml/min./kg) [40] , k a is the absorption rate constant and F a is the fraction of the dose absorbed. In the absence of reported parameters (table 1) , the F a , B/P, and k a values of the inhibitors were assumed to be 0.8, 0.55 and 0.03 1/min., respectively [4, 38] .
Predictions based on both reversible and mechanism-based inhibition of intestinal CYP3A4 were conducted using intestinal inhibitor concentrations, [I] G .
[I] G values were estimated using the following equation [41] :
where Q ent is the enterocytic blood flow (300 ml/min) [42] .
[I] G values were calculated assuming no binding of the inhibitor to enterocytic proteins (f u,gut = 1). Drug-drug interaction predictions were carried out using midazolam and simvastatin as the CYP3A4 victim drugs, assuming that their f m, CYP3A4 and F G values correspond to 0.94 and 0.51 for midazolam and 0.90 and 0.14 for simvastatin [43] [44] [45] . Interaction predictions based on CYP2C8 inhibition were conducted for a CYP2C8-dependent drug with an f m,CYP2C8 of 0.9, such as dasabuvir and daprodustat [25] . CYP2C8 inhibition was assumed to occur in liver only.
Results

Direct and time-dependent inhibition of CYP2C8 in HLM incubations.
None of the tested kinase inhibitors affected CYP2C8 by time-dependent inhibition (IC 50 shift <1.5) (table 2) . Masitinib, trametinib and vatalanib inhibited CYP2C8 activity with low reversible IC 50 values of <5 lM. However, CYP2C8 inhibition by midostaurin and nintedanib was weak, and the highest midostaurin and nintedanib concentrations tested (117 and 75 lM) caused only 32% and 12% reversible inhibition. Preincubation with NADPH did not increase the inhibitory effect (32% and <5% inhibition, respectively).
Direct and time-dependent inhibition of CYP3A4 in HLM incubations. Masitinib, midostaurin, trametinib and vatalanib inhibited CYP3A4 with low reversible IC 50 values of ≤4 lM, while the IC 50 values for dovitinib and nintedanib were at least an order of magnitude greater (table 2) . Pre-incubation of midostaurin with NADPH resulted in a further 15-fold decrease in its IC 50 value for CYP3A4 inhibition to 0.088 lM (table 2) . Similarly, following pre-incubation with NADPH, the IC 50 value for CYP3A4 inhibition by dovitinib decreased by a factor of 3 (IC50 = 61lM). The highest nintedanib concentration tested (75 lM), reduced the activity of CYP3A4 by 53%. Following pre-incubation with NADPH, its CYP3A inhibitory effect was increased by a factor of 4 (IC 50 = 21 lM). Dovitinib, midostaurin and nintedanib were therefore further tested in mechanism-based inhibition experiments.
Mechanism-based inhibition of CYP3A4.
The inhibition of CYP3A4 activity by midostaurin and nintedanib was concentration-, NADPH-and pre-incubation timedependent ( fig. 1) Mechanistic experiments with midostaurin and nintedanib.
In subsequent experiments, the competitive CYP3A4 inhibitor ketoconazole reduced the nintedanib-induced inactivation of CYP3A4 in a concentration-dependent manner ( fig. 2) . Unexpectedly, the inactivation of CYP3A4 by midostaurin was not affected by ketoconazole, possibly due to binding of ketoconazole to a different substrate binding site of CYP3A4 than midostaurin. An alternative competitive CYP3A4 inhibitor, saquinavir, on the other hand, reduced the inactivation of CYP3A4 by midostaurin. Furthermore, trapping agents such as glutathione, mannitol and superoxide dismutase did not affect the inactivation of CYP3A4 by midostaurin, suggesting that the inactivating agent is formed at and remains bound to the active site of CYP3A4 ( fig. 2) . Similarly, dialysis of preincubated HLM-midostaurin and HLM-nintedanib mixtures for 3 9 2 hr at 4°C did not abolish their inhibitory effects on midazolam 1 0 -hydroxylation (data not shown), also indicating that observed inactivation of CYP3A4 by midostaurin and nintedanib can be classified as irreversible.
Prediction of in vivo drug interactions due to inhibition of CYP2C8 or CYP3A4.
The predicted maximal fold increase in the AUC of a sensitive CYP2C8 substrate (f m, CYP2C8 = 0.9) is shown in fig. 3A . Masitinib and vatalanib were predicted to cause maximal AUC increases of~2-fold, whereas predictions for dovitinib and trametinib resulted in minimal AUC increases (≤1.1-fold).
The predicted maximal fold increases in the AUCs of midazolam and simvastatin as the CYP3A4 victim drugs are shown in fig. 3B . Strong interactions (AUC increases of ≥5-fold) were predicted between masitinib, midostaurin and vatalanib and the victim substrates, while predictions with dovitinib, nintedanib and trametinib resulted in minor interactions (≤1.3-fold). In the case of midostaurin, mechanism-based inhibition of CYP3A4 alone explained most of the predicted increase in AUC, while reversible inhibition played a minor role.
Discussion
Many protein kinase inhibitors have been reported to affect CYP3A4 by time-dependent inhibition. In the present study, a set of six kinase inhibitors were investigated for their inhibitory effects on CYP2C8 and CYP3A4 activity ( fig. 4) . In an initial assessment, none of the inhibitors affected CYP2C8 by time-dependent inhibition, but dovitinib, midostaurin and nintedanib exhibited time-dependent inhibition of CYP3A4. While dovitinib did not cause inactivation of CYP3A4 in further experiments, midostaurin and nintedanib were identified as irreversible mechanism-based inhibitors of CYP3A4. In line with the criteria for mechanism-based inhibition [17] , the following observations were made: the inhibitory effects on CYP3A4 activity by midostaurin and nintedanib were dependent on pre-incubation time, inhibitor concentration and NADPH; the presence of a competitive inhibitor decreased the inhibition; and dialysis was unable to restore enzyme activity.
The multikinase inhibitor midostaurin and the triple angiokinase inhibitor nintedanib did not even cause significant reversible inhibition of CYP2C8 with concentrations up to 117 lM and 75 lM, respectively (table 2). However, for CYP3A4, 50 values, and more detailed investigations revealed that they affect CYP3A4 by mechanism-based inhibition (figs 1 and 2). Our predictions suggested that inactivation of CYP3A4 by nintedanib is unlikely to cause clinically significant drugdrug interactions, while midostaurin was predicted to markedly increase the plasma exposure to CYP3A4 substrate drugs ( fig. 3) . Interestingly, however, midostaurin has had no effect on midazolam pharmacokinetics in healthy individuals, when midazolam was given with a single midostaurin dose (100 mg) or 48 hr after multiple midostaurin doses (50 mg twice daily for 4 days, followed by midazolam administration 48 hr after the last midostaurin dose) [59] . Furthermore, repeated dosing of midostaurin for 4 days was not accompanied by any notable changes in endogenous CYP3A4 marker activities [59] . Although these observations failed to show that midostaurin acts as a CYP3A4 inhibitor in vivo, it seems that the designs of these studies did not capture the time-point when midostaurin plasma concentrations and resulting CYP3A4 inhibition are likely to peak. Midostaurin exhibits time-dependent pharmacokinetics, with a disproportionate increase in plasma concentrations during the first 3-7 days of therapy, followed by a 60-70% decline in concentrations until a steady-state is reached at 26-28 days [51] [52] [53] 60] . These clinical data indicate that midostaurin inhibits its own CYP3A4-mediated metabolism during the first week of therapy, followed by strong auto-induction surpassing the initial CYP3A4 inhibitory effects. Time-dependent inhibition and induction of CYP3A4 caused by midostaurin and its two major metabolites are likely to explain the time-dependent pharmacokinetics of midostaurin [53, 61] . In this light, our interaction predictions for midostaurin could be viewed as a possible worst-case scenario that could occur during some of (table 1) . For CYP3A4, inhibition of hepatic enzyme only (HEP) and of both hepatic and intestinal enzyme (HEP + INT) are shown. The predictions based on time-dependent inhibition were conducted using typical unbound peak concentrations of the inhibitors, [I] max,u , while those based on reversible inhibition were carried out using approximated unbound peak hepatic inlet concentrations, [I] u,inlet,max . For the mechanism-based inhibitors midostaurin and nintedanib, the black-coloured bars denote the maximal interaction magnitude due to reversible inhibition only. It should be noted that masitinib, midostaurin, trametinib and vatalanib have been reported to affect CYP3A4 by induction in vitro, and this interaction mechanism has not been taken into account in the predictions. AUC, area under the concentration-time curve; DOVI, dovitinib; MASI, masitinib; MIDO, midostaurin; NINTE, nintedanib; TRAME, trametinib; VATA, vatalanib. Each experiment is compared with its own control, that is, either preincubation without kinase inhibitor or pre-incubation with competitive inhibitor/trapping agent but without kinase inhibitor. In the experiments, 30-min. pre-incubations including human liver microsomes (0.5 mg/ml) and NADPH were conducted with or without competitive inhibitor/trapping agent, in both the absence (controls) and presence of kinase inhibitor, followed by 20-fold dilution for measurement of residual CYP3A4 activity. Values are expressed as mean AE S.D. of duplicates (controls were carried out as triplicates). GSH, glutathione; MANN, mannitol; MIDO, midostaurin; NINTE, nintedanib; SOD, superoxide dismutase. the first days of midostaurin treatment. Taken together, our finding showing that midostaurin affects CYP3A4 by mechanism-based inhibition adds a further layer to the relationship between midostaurin and CYP3A4, and may be used to improve predictions of midostaurin pharmacokinetics and interaction potential. In the clinical setting, care is warranted in dosing of CYP3A4 substrates during the first few days of midostaurin treatment, while higher drug doses may be necessary after 1-2 weeks of midostaurin treatment.
Based on the present findings, the risk of interaction between dovitinib and CYP2C8 substrates is likely to be low ( fig. 3 ). For CYP3A4, however, pre-incubation of dovitinib with NADPH caused a threefold shift in its IC 50 , initially suggesting a potential for time-dependent inhibition. Unexpectedly, in the kinetic assessment, high concentrations of dovitinib did not inhibit CYP3A4 activity. One explanation for this discrepancy may be that the time-dependent inhibition initially observed is, in fact, reversible inhibition caused by a metabolite of dovitinib. Following dilution in the kinetic assessment experiment, the concentrations of such a metabolite are likely to be too low to cause inhibition. Because no metabolites of dovitinib were commercially available, the CYP3A4 inhibition by dovitinib was not further studied. Hence, predictions were based on its reversible IC 50 value only and suggested minor interactions with CYP3A4 substrates (≤1.3-fold increases in AUC). Dovitinib is a strong CYP1A inducer and has markedly (by >90%) reduced the plasma exposures to the CYP1A marker substrate caffeine and to erlotinib, a CYP1A and CYP3A4 substrate, in human beings [62] . No other interaction studies have hitherto been reported.
Masitinib, trametinib and vatalanib inhibited CYP2C8 and CYP3A4 with low reversible IC 50 values (≤5 lM). Although our predictions indicate that clinically relevant interactions between trametinib and CYP2C8 and CYP3A4 substrates are unlikely, the previously determined R value for CYP2C8 inhibition by trametinib (1.24) does not exclude interactions with CYP2C8 [63] . In contrast, our predictions for masitinib and vatalanib suggest that they may increase the AUCs of sensitive CYP2C8 and CYP3A4 substrates by more than twofold ( fig. 3 ). However, similar to midostaurin, both masitinib and vatalanib are also CYP3A4 inducers [58, 64] . While no interaction studies have been published for masitinib and trametinib, one study reports that co-administration of vatalanib and paclitaxel, a CYP2C8 and CYP3A4 substrate, increased paclitaxel clearance by 30-80% in patients [65] . Until clinical interaction studies have unravelled the net effects of these inhibitors on CYP2C8 and CYP3A4, they should be used with caution in patients using CYP2C8 and CYP3A4-dependent drugs.
It is important to be aware of the limitations of the predictions carried out on the basis of the present in vitro data. Most notably, interaction mechanisms other than reversible and time-dependent inhibition of CYP2C8 and CYP3A4 were not accounted for in our predictions. Four of the tested protein kinase inhibitors (masitinib, midostaurin, trametinib and vatalanib) have been reported to induce CYP3A4 in vitro. Furthermore, our predictions only considered inhibition by the parent compounds. The inhibitors tested may have major metabolites that contribute to their overall interaction potential, as mentioned with regard to midostaurin above. Finally, the static model has been associated with over-estimations of timedependent inhibition potential, in particular when the intestinal component is included in the predictions [4, 38] . Although many kinase inhibitors have been shown to affect CYP3A4 by time-dependent inhibition, their in vivo interactions with CYP3A4 have generally been moderate or weak [4] . On the other hand, static models have also often underestimated interactions due to reversible inhibition.
In mechanism-based inhibition, the inhibitor is metabolized to a reactive intermediate, which permanently inactivates the metabolizing enzyme [17] . Numerous structural elements have been suggested to cause mechanism-based inhibition [66] . For instance, the piperazine and p-toluidine moieties of imatinib have been proposed to undergo hydroxylation and desaturation to imine and imine-methide intermediates [24] . Quinone-imines and iminemethides are reactive electrophiles, which besides binding to CYP enzymes, may also form adducts with other cellular proteins and initiate idiosyncratic reactions in Fig. 4 . Summary of the present findings. According to the present data, midostaurin and nintedanib are reversible inhibitors of CYP2C8 but irreversible time-dependent inhibitors of CYP3A4 in human liver microsomes. Irreversible time-dependent inhibition may have implications not only for drug-drug interactions but also for liver toxicity. The other inhibitors tested, dovitinib, masitinib, trametinib and vatalanib, affected CYP2C8 and CYP3A4 by reversible inhibition.
hepatocytes [19] . Although we did not undertake any studies to identify the structures of the reactive intermediates formed in the bioactivation processes of midostaurin and nintedanib, it can be possible that some of the reactive metabolites formed by the hepatic CYP3A4 enzymes are involved in mechanisms of hepatotoxicity. At least nintedanib treatment has been associated with hepatotoxicity; in a phase II trial, 51% of patients receiving nintedanib 250 mg twice daily developed grade 3 or 4 liver toxicity, as compared to 7.5% in the placebo group [67] .
Many protein kinase inhibitors affect CYP enzymes, in particular CYP3A4, by mechanism-based inhibition. In addition to drug-drug interactions and idiosyncratic reactions, a third possible consequence of this inhibition type is autoinhibition of the metabolism of the inhibitor itself, as proposed for imatinib [2, 27, 68] . CYP3A4 seems to play a minor role in the metabolism of nintedanib [54] , while it is a key enzyme in the elimination of midostaurin [51, 59] . Autoinhibition of a drugmetabolizing enzyme crucial in the metabolism of the inhibitor itself may lead to increasing importance of other, minor enzymes with time. Given the fact that midostaurin seems to affect CYP3A4 by both induction and mechanism-based inhibition, further studies will be needed to elucidate the timecourse of its effects on CYP3A4 activity. Speaking in general terms, however, variability in CYP3A4 expression or activity together with mechanism-based CYP3A4 inhibition may partly explain the great interindividual variations observed in kinase inhibitor concentrations.
In conclusion, according to the findings of this study, masitinib and vatalanib are potent reversible inhibitors of CYP2C8 and CYP3A4, and may therefore alter the concentrations of CYP2C8-and CYP3A4-dependent drugs in vivo. Our study also shows that midostaurin and nintedanib affect CYP3A4 by irreversible mechanism-based inhibition, which may have implications in terms of their drug-drug interactions and liver toxicity. Further investigations are needed to elucidate the clinical relevance of these findings.
